Teva Pharmaceutical Industries Says US FDA Accepted its sBLA Filing for AJOVY

MT Newswires Live2025-04-07

Teva Pharmaceutical Industries (TEVA) said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.

The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.

Teva's share price rose more than 5% in recent premarket activity.

Price: 14.54, Change: +0.74, Percent Change: +5.36

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2525120700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-07 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525120700","market":"us","top_or_hot":-1,"title":"Teva Pharmaceutical Industries Says US FDA Accepted its sBLA Filing for AJOVY","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries (TEVA) said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.</p><p>The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.</p><p>Teva's share price rose more than 5% in recent premarket activity.</p><p>Price: 14.54, Change: +0.74, Percent Change: +5.36</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Industries Says US FDA Accepted its sBLA Filing for AJOVY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Industries Says US FDA Accepted its sBLA Filing for AJOVY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-07 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical Industries (TEVA) said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.</p><p>The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.</p><p>Teva's share price rose more than 5% in recent premarket activity.</p><p>Price: 14.54, Change: +0.74, Percent Change: +5.36</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2525120700","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525120700","pubTimestamp":1744027273,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries  said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.Teva's share price rose more than 5% in recent premarket activity.Price: 14.54, Change: +0.74, Percent Change: +5.36","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","TEVA":"梯瓦制药","BK4584":"避孕概念","BK4566":"资本集团","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股"},"translate_title":"梯瓦制药工业公司表示美国FDA接受了其AJOVY的sBLA申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries (TEVA) said Monday the US Food and Drug Administration has accepted its US affiliate Teva Pharmaceuticals' supplemental biologics license application for AJOVY to expand the indication to include the prevention of episodic migraine in certain pediatric patients.The application was based on results from the phase 3 SPACE trial which demonstrated statistically significant improvements in reducing monthly migraine days and monthly headache days using AJOVY compared to a placebo, the company said.Teva's share price rose more than 5% in recent premarket activity.Price: 14.54, Change: +0.74, Percent Change: +5.36","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2525120700","isCrawlerRequest":true}